To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Summary

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Difficult to Control Hypertension

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

E-Star BioTech, LLC

Last updated on ClinicalTrials.gov

September 23, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites